title: Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.
abstract: The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 x 10(9)/l neutrophils of 10 days (range 8-13) and 20 x 10(9)/l platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.
authors.affiliation: Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: T
authors.initials: T
authors.lastname: Chou
authors.forename: K
authors.initials: K
authors.lastname: Tobinai
authors.forename: R
authors.initials: R
authors.lastname: Tanosaki
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: M
authors.initials: M
authors.lastname: Taniwaki
authors.forename: A
authors.initials: A
authors.lastname: Hiraoka
authors.forename: M
authors.initials: M
authors.lastname: Tanimoto
authors.forename: T
authors.initials: T
authors.lastname: Koike
authors.forename: K
authors.initials: K
authors.lastname: Kogawa
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: T
authors.initials: T
authors.lastname: Hotta
mesh_terms: D000328:Adult; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002999:Clone Cells; D005260:Female; D015321:Gene Rearrangement; D006085:Graft Survival; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D018189:Immunomagnetic Separation; D016130:Immunophenotyping; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D016133:Polymerase Chain Reaction; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D007143:Immunoglobulin Heavy Chains